These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23409032)

  • 1. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
    Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
    PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
    Salomon A; Keramidas M; Maisin C; Thomas M
    Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXIN genetic analysis in adrenocortical carcinomas updated.
    Guimier A; Ragazzon B; Assié G; Tissier F; Dousset B; Bertherat J; Gaujoux S
    J Endocrinol Invest; 2013 Dec; 36(11):1000-3. PubMed ID: 23812285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
    Chapman A; Durand J; Ouadi L; Bourdeau I
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
    Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
    Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
    Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
    Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
    Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
    J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
    Leal LF; Bueno AC; Gomes DC; Abduch R; de Castro M; Antonini SR
    Oncotarget; 2015 Dec; 6(40):43016-32. PubMed ID: 26515592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process.
    He H; Dai J; Yang X; Wang X; Sun F; Zhu Y
    Biol Chem; 2018 May; 399(6):593-602. PubMed ID: 29730647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.
    Abduch RH; Carolina Bueno A; Leal LF; Cavalcanti MM; Gomes DC; Brandalise SR; Masterallo MJ; Yunes JA; Martinelli CE; Tone LG; Tucci S; Molina CA; Ramalho FS; Moreira AC; Cardinalli IA; Scrideli CA; Ramalho LN; de Castro M; Antonini SR
    Oncotarget; 2016 Dec; 7(51):84634-84644. PubMed ID: 27705928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
    Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
    Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTNNB1 Knockdown Inhibits Cell Proliferation and Aldosterone Secretion Through Inhibiting Wnt/β-Catenin Signaling in H295R Cells.
    Zhou T; Luo P; Wang L; Yang S; Qin S; Wei Z; Liu J
    Technol Cancer Res Treat; 2020; 19():1533033820979685. PubMed ID: 33287648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells.
    Doghman M; Cazareth J; Lalli E
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3222-5. PubMed ID: 18544621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
    Liu-Chittenden Y; Jain M; Gaskins K; Wang S; Merino MJ; Kotian S; Kumar Gara S; Davis S; Zhang L; Kebebew E
    Oncogene; 2017 Jun; 36(25):3541-3552. PubMed ID: 28114280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.